Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a

MELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX

Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 i

MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot

– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide

Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ:AT

Alterity Therapeutics Limited (NASDAQ:ATHE) stock is up during Tuesday's session as the biotechnolog

Alterity Therapeutics advances ATH434 toward Phase 3 after FDA alignment on trial design for MSA, wh

– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design

"These data continue to strengthen the evidence that ATH434 has the potential to be the first di

– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical

– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disea

– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disea

MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:

Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the plann

Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in

This second Type C Meeting builds on Alterity's recent regulatory interactions with the FDA and

MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS

- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite

- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite

MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS

NovoCure (NASDAQ: NVCR - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report)

Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) was the recipient of

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot

Alignment reached on key elements of ATH434 Phase 3 development program Alignment reached on key ele

Alterity Therapeutics (NASDAQ: ATHE) outlined its development strategy for lead drug candidate ATH43

Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) saw a large growth in

MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biot

– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New an

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot

Alterity Therapeutics Limited (‘ATH'): ASX Aware LetterASX refers to the following:A.ATH's a

– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurol

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot

Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidanc

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot

– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints ––